Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Melanoma Risk Assessed in Melanoma-Prone Families

J Invest Dermatol; ePub 2018 Feb 2; Tucker, Elder, et al

Prospective risk of melanoma has decreased substantially in both mutation-positive and mutation-negative families over 4 decades, while melanoma has greatly increased in the general population, a recent study found. Researchers assessed risks of melanoma and other cancers in 1,226 members of 56 families followed for up to 4 decades to population rates in the Surveillance, Epidemiology, and End Results (SEER) program. All families were tested for mutations in CDKN2A and CDK4; 29 were mutation-positive and 27 mutation-negative. They compared rates of invasive melanomas, both first and second, by family mutation status, to SEER. Findings included:

  • Comparing 3 calendar periods of the study, risk of first primary melanoma decreased slightly.
  • Risks of melanoma after first examination, however, were approximately one-third the risks prior to the first examination, in both mutation-positive and mutation-negative families.
  • Among patients with melanoma, risk of a second melanoma was increased 10-fold in all families; risk was somewhat higher in mutation-positive families.
  • Risks of other second cancers were increased only for pancreatic cancer after melanoma in mutation-positive families.
Citation:

Tucker MA, Elder DE, Curry M, et al. Risks of melanoma and other cancers in melanoma-prone families over four decades. [Published online ahead of print February 2, 2018]. J Invest Dermatol. doi:10.1016/j.jid.2018.01.021.

This Week's Must Reads

Opioids and the Dermatology Medicare Population, JAMA Dermatology; ePub 2018 Feb 7; Cao, et al

Significant Care Costs Associated with Cellulitis, J Am Acad Dermatol; ePub 2018 Feb 7; St. John, et al

An Analysis of Adherence to Melanoma Treatment , J Clin Aesthet Dermatol; 2017 Dec; Reserva, et al

Underlying Disease Impact on Pyoderma Gangrenosum, J Am Acad Dermatol; ePub 2018 Feb 10; Kaffenberger, et al

FDA Approves Label Update for Cosentyx, Novartis news release; 2018 Feb 8

Must Reads in Melanoma

An Analysis of Adherence to Melanoma Treatment , J Clin Aesthet Dermatol; 2017 Dec; Reserva, et al

Melanoma Risk Assessed in Melanoma-Prone Families, J Invest Dermatol; ePub 2018 Feb 2; Tucker, Elder, et al

Validity of Transplant Network Cancer Reporting , J Am Acad Dermatol; 2018 Feb; Garrett, et al

2-mm Biopsy Margin May Decrease Patient Morbidity, J Am Acad Dermatol; 2017 Dec; Terushkin, Ng, et al

Inverted Type-A Melanocytic Nevi Examined, J Cutan Pathol; ePub 2018 Jan 17; Dadras, et al